JPS58102159A - 安定な基本血清組成物の製造方法 - Google Patents
安定な基本血清組成物の製造方法Info
- Publication number
- JPS58102159A JPS58102159A JP57147860A JP14786082A JPS58102159A JP S58102159 A JPS58102159 A JP S58102159A JP 57147860 A JP57147860 A JP 57147860A JP 14786082 A JP14786082 A JP 14786082A JP S58102159 A JPS58102159 A JP S58102159A
- Authority
- JP
- Japan
- Prior art keywords
- serum
- method described
- preceding paragraph
- composition
- calibration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002966 serum Anatomy 0.000 title claims description 80
- 239000000203 mixture Substances 0.000 title claims description 10
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 238000000034 method Methods 0.000 claims description 42
- 238000001914 filtration Methods 0.000 claims description 11
- 239000012888 bovine serum Substances 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 230000003287 optical effect Effects 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 230000003466 anti-cipated effect Effects 0.000 claims description 3
- 150000007529 inorganic bases Chemical class 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 150000007530 organic bases Chemical class 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 3
- 239000005909 Kieselgur Substances 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 claims 1
- 229910001948 sodium oxide Inorganic materials 0.000 claims 1
- 238000003860 storage Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N carnosic acid Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- LFEINUNSYODISY-UHFFFAOYSA-N (ent-5alpha,6beta)-15,16-Epoxy-3,13(16),14-clerodatrien-18,6-olide Natural products CC1CC(C23C)OC(=O)C3=CCCC2C1(C)CCC=1C=COC=1 LFEINUNSYODISY-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101150082208 DIABLO gene Proteins 0.000 description 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 1
- 244000061354 Manilkara achras Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
- G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/825—Pretreatment for removal of interfering factors from sample
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/106664—Blood serum or blood plasma standard or control
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25125—Digestion or removing interfering materials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/2525—Stabilizing or preserving
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6/325791 | 1981-11-30 | ||
| US06/325,791 US4438202A (en) | 1981-11-30 | 1981-11-30 | Stable, base serum compositions and preparation thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2417971A Division JPH0666811A (ja) | 1981-11-30 | 1990-12-19 | 血清中間体の製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58102159A true JPS58102159A (ja) | 1983-06-17 |
| JPH0437383B2 JPH0437383B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1992-06-19 |
Family
ID=23269466
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57147860A Granted JPS58102159A (ja) | 1981-11-30 | 1982-08-27 | 安定な基本血清組成物の製造方法 |
| JP2417971A Pending JPH0666811A (ja) | 1981-11-30 | 1990-12-19 | 血清中間体の製造方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2417971A Pending JPH0666811A (ja) | 1981-11-30 | 1990-12-19 | 血清中間体の製造方法 |
Country Status (5)
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6061660A (ja) * | 1983-08-22 | 1985-04-09 | テクニコン、インストルメンツ、コーポレーシヨン | 光学的に透明な血清トリグリセリド組成物 |
| JPS61142467A (ja) * | 1984-12-10 | 1986-06-30 | ベーリンガー・マンハイム・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 脂質診断学用の管理血清もしくは検定用血清及びその製造法 |
| JPH0666811A (ja) * | 1981-11-30 | 1994-03-11 | Technicon Instr Corp | 血清中間体の製造方法 |
| WO2006054519A1 (ja) * | 2004-11-17 | 2006-05-26 | Kyowa Medex Co., Ltd. | リポ蛋白中成分の分別定量用標準品 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3324626A1 (de) * | 1983-07-08 | 1985-01-17 | Boehringer Mannheim Gmbh, 6800 Mannheim | Lagerstabiles universalkontrollserum |
| DE3812610A1 (de) * | 1988-04-15 | 1989-10-26 | Boehringer Mannheim Gmbh | Verfahren zur bestimmung der thyroxinbindekapazitaet und dazu geeignete standardloesung |
| DE4135404A1 (de) * | 1991-10-26 | 1993-04-29 | Boehringer Mannheim Gmbh | Stabiles fluessiges kontroll- bzw. eichserum fuer die klinische diagnostik |
| US5296377A (en) * | 1992-12-15 | 1994-03-22 | Boehringer Mannheim Corporation | Control reagent containing a hydroxylamine or an antioxidant |
| US5385844A (en) * | 1993-04-22 | 1995-01-31 | Boehringer Mannheim Corporation | Polymer containing control reagents and polymers useful in control reagents |
| EP0866134A3 (en) * | 1997-03-17 | 1999-12-22 | Hitachi, Ltd. | A calibrator for measuring enzyme activity, and a method for measuring enzyme activity using the same |
| US6248869B1 (en) | 1997-05-29 | 2001-06-19 | Medical Analysis Systems, Inc. | Troponin I forms and use of the same |
| US6618325B1 (en) | 1998-11-10 | 2003-09-09 | Vanzandt Thomas R. | Method and apparatus for controlling damping and in situ determination of frequency response for high bandwidth force-balance single-coil geophone |
| GB201102794D0 (en) | 2011-02-17 | 2011-03-30 | Metail Ltd | Online retail system |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55164360A (en) * | 1979-06-04 | 1980-12-22 | Du Pont | Making of defatted serum and plasma |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2353035B2 (de) * | 1973-10-23 | 1979-10-31 | Behringwerke Ag, 3550 Marburg | Verfahren zur Stabilisierung menschlicher oder tierischer Körperflüssigkeiten oder pflanzlicher Extrakte |
| US3955925A (en) | 1973-11-12 | 1976-05-11 | Proksch Gary J | Preparation of optically clear serum |
| US4045176A (en) | 1975-06-13 | 1977-08-30 | Proksch Gary J | Preparation of optically clear serum |
| US4007008A (en) * | 1975-07-30 | 1977-02-08 | Becker Milton J | Preparation of reference serum from animal blood |
| US4158544A (en) | 1978-07-17 | 1979-06-19 | Beckman Instruments, Inc. | Process for preparing a biological composition for use as a reference control in diagnostic analysis |
| US4438202A (en) * | 1981-11-30 | 1984-03-20 | Technicon Instruments Corporation | Stable, base serum compositions and preparation thereof |
-
1981
- 1981-11-30 US US06/325,791 patent/US4438202A/en not_active Expired - Fee Related
-
1982
- 1982-07-15 CA CA000407354A patent/CA1182395A/en not_active Expired
- 1982-08-27 JP JP57147860A patent/JPS58102159A/ja active Granted
- 1982-10-13 DE DE8282305441T patent/DE3268698D1/de not_active Expired
- 1982-10-13 EP EP82305441A patent/EP0082587B1/en not_active Expired
-
1990
- 1990-12-19 JP JP2417971A patent/JPH0666811A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55164360A (en) * | 1979-06-04 | 1980-12-22 | Du Pont | Making of defatted serum and plasma |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0666811A (ja) * | 1981-11-30 | 1994-03-11 | Technicon Instr Corp | 血清中間体の製造方法 |
| JPS6061660A (ja) * | 1983-08-22 | 1985-04-09 | テクニコン、インストルメンツ、コーポレーシヨン | 光学的に透明な血清トリグリセリド組成物 |
| JPS61142467A (ja) * | 1984-12-10 | 1986-06-30 | ベーリンガー・マンハイム・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 脂質診断学用の管理血清もしくは検定用血清及びその製造法 |
| WO2006054519A1 (ja) * | 2004-11-17 | 2006-05-26 | Kyowa Medex Co., Ltd. | リポ蛋白中成分の分別定量用標準品 |
| JP4704355B2 (ja) * | 2004-11-17 | 2011-06-15 | 協和メデックス株式会社 | リポ蛋白中成分の分別定量用標準品 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA1182395A (en) | 1985-02-12 |
| JPH0666811A (ja) | 1994-03-11 |
| EP0082587A1 (en) | 1983-06-29 |
| US4438202A (en) | 1984-03-20 |
| JPH0437383B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1992-06-19 |
| DE3268698D1 (en) | 1986-03-06 |
| EP0082587B1 (en) | 1986-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS58102159A (ja) | 安定な基本血清組成物の製造方法 | |
| Fraenkel-Conrat | Degradation of tobacco mosaic virus with acetic acid | |
| US4158544A (en) | Process for preparing a biological composition for use as a reference control in diagnostic analysis | |
| Badin et al. | Plasma polysaccharide fraction containing uronic acid, in normal subjects and in patients with rheumatoid arthritis | |
| Cohn | Chemical, physiological, and immunological properties and clinical uses of blood derivatives | |
| Mills et al. | Excretions and secretions of Trichinella spiralis and their role in immunity | |
| Goldmann et al. | Isolation and characterization of the brush border fraction from newborn rat renal proximal tubule cells | |
| Philpot | The behaviour of pepsin in the ultracentrifuge after alkaline inactivation | |
| US2793203A (en) | Process of preparing stable, highly purified gamma globulin preparations | |
| KR20220036822A (ko) | 생물학적 시료의 안정적인 수집 및 보관 방법 | |
| Howe | The influenza virus receptor and blood group antigens of human erythrocyte stroma | |
| Taylor et al. | Isolation and properties of a macromolecular component of normal chick embryo tissue | |
| RU2621311C1 (ru) | Способ получения протеогликана | |
| CN115791354B (zh) | 一种精子dna碎片化检测用质控品及其制备方法和应用 | |
| US3993585A (en) | Elevated human lipids control | |
| Erickson et al. | Antigenic properties of native and regenerated horse serum albumin | |
| EP0339531B1 (en) | Physiological active liquid allergenic composition from biological raw materials | |
| RU2087150C1 (ru) | Способ получения церулоплазмина | |
| JPH10282105A (ja) | 血清アミロイドａ測定用キャリブレーターの製造方法 | |
| Doery | The separation and properties of the neurotoxins from the venom of the tiger snake Notechis scutatus scutatus | |
| Webster et al. | A turbidimetric method for assay of Vi antigen | |
| US2741653A (en) | Method of isolating nucleoproteins | |
| Maurer | Immunochemical comparisons of various gelatins and their derivatives | |
| RU2338375C2 (ru) | Способ хранения плазмы или сыворотки крови для получения иммуноглобулиновых и альбуминовых биопрепаратов | |
| US2369111A (en) | Blood clotting accelerator |